Time for the US FDA to "realize its full potential"

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1472, 2005-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Disease Registries: Challenges and Opportunities to Realize Their Full Potential

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 2, Iss. 2, 2015-08 ,pp. : 86-89

Bentham Science Publishers

Access to resources Recommend Favorite

US FDA shows its teeth with Rotarix approval

By  

Reactions Weekly, Vol. 1, Iss. 1200, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

US FDA sets its sights on the developing world

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Efavirenz [`Sustiva'] is the first antiretroviral to be granted traditional (full) approval by the US FDA

By  

Inpharma, Vol. 1, Iss. 1226, 2000-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

US FDA news

By  

Inpharma, Vol. 1, Iss. 1231, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite